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Abstract
We evaluated the mechanisms of thrombocytopenia and procoagulant changes in relation with clinical variables in a cohort of
patients with acute hantavirus disease.
Blood samples of 33 prospectively recruited, consecutive, hospitalized patients with acute Puumala virus–induced hemorrhagic
fever with renal syndrome (HFRS) were collected acutely and at the recovery visit (control). Serum thrombopoietin (TPO) and activity
of plasmamicroparticles (MPs) from various cell sources were measured with enzyme-linked immunosorbent assay-basedmethods.
The results were related to data on platelet indices and functions, coagulation variables, and clinical disease.
Serum TPO was nearly 4-fold higher acutely compared with the control (median 207pg/mL, range 56–1258pg/mL vs. median 58
pg/mL, range 11–241pg/mL, P<0.001) and coincided with high mean platelet volume (MPV) and immature platelet fraction (IPF%).
Prothrombin fragments and D-dimer were high acutely compared with the control (F1+2median 704pmol/L, range 284–1875pmol/
L vs. median 249pmol/L, range 118–556pmol/L, P<0.001; D-dimer median 2.8mg/L, range 0.6–34.0mg/L vs. median 0.4mg/L,
range 0.2–1.1mg/L, P<0.001), and associated with low platelet count and severe acute kidney injury (AKI). MPs’ procoagulant
activity was high acutely only among patients with mild AKI (plasma creatinine below the median at the time of the measurement).
Upregulated TPO together with high MPV and IPF% conﬁrm active thrombopoiesis, but do not predict severity of HFRS.
Simultaneously, elevated prothrombin fragments and D-dimer suggest increased consumption of platelets in patients with severe
AKI. Activity of platelet-derived MPs in HFRS should be studied with ﬂow cytometry in a larger cohort of patients.
Abbreviations: AKI = acute kidney injury, ALT = alanine aminotransferase, CRP = C-reactive protein, HCPS = hantavirus
cardiopulmonary syndrome, HFRS = hemorrhagic fever with renal syndrome, HIV = human immunodeﬁciency virus, IL-6 =
interleukin 6, IPF% = immature platelet fraction %, MP = microparticle, MPV = mean platelet volume, PFA-100 = platelet factor
analyzer 100, PUUV = Puumala virus, STAT = signal transducers and activators of transcription, TF = tissue factor, TGFb =
transforming growth factor b, TPO = thrombopoietin.
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11. Introduction
Hantaviruses are enveloped RNA viruses belonging to the family
of Bunyaviridiae. In humans, they give rise to a spectrum of
illnesses called hemorrhagic fever with renal syndrome (HFRS) in
Eurasia and hantavirus cardiopulmonary syndrome (HCPS) in
the Americas. HCPS carries a mortality rate of 40%, whereas the
mortality in HFRS is lower (0.4%–15%), but the incidence of
HFRS is substantially higher. Classically,HFRSoccurs in 5distinct
phases: febrile, hypotensive, oliguric, polyuric, and convalescent.
Capillary leakage, thrombocytopenia, and acute kidney injury
(AKI) are the key elements in the pathogenesis of HFRS. Speciﬁc
treatment is not available for hantavirus infection.[1]
Low platelet count is a hallmark of hantavirus disease, but the
severity of bleeding symptoms varies according to the hantavirus
species. Signs of bleeding can be noted in up to one-third of the
patients infected with the most common European hantavirus,
Puumala virus (PUUV). Hemorrhage has been documented
in various organs in fatal cases,[2] and mild mucocutaneous
involvement has been reported in general. However, thrombo-
embolic complications and increased risk of acute myocardial
infarction and stroke have been reported to associate with PUUV-
induced HFRS in Swedish patients.[3,4] The individual balance
between enhanced and hampered coagulation prevails and
remains challenging.
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disease progression and binding to ﬁbrin-covered endothelial
cells as a mechanism leading to the decreased platelet count
during acute hantavirus infection.[1] Upregulated tissue factor
(TF) expression on the infected endothelial cells is suggested to
induce increased thrombin formation noted during PUUV
infection.[5,6] Compatibly with endothelial cell activation,
elevated level of tissue plasminogen activator and D-dimer have
both been observed.[6,7] Findings of enhanced platelet ligands are
in concordance with those of increased platelet activation.[8,9]
Large mean platelet volume (MPV) and immature platelet
fraction % (IPF%) together with elevated serum thrombopoietin
(TPO) level imply active thrombopoiesis.[9,10] Despite increased
platelet production the aggregation is, however, impaired.[10]
We here studied serum TPO level and the procoagulant activity
of plasma microparticles (MPs) in 33 Finnish patients who were
treated in hospital for acute PUUV infection. We analyzed the
results in relation with clinical data, platelet function tests in
whole blood (platelet function analyzer PFA-100 and Multi-
plate), and coagulation variables available. Our aim was to study
whether active thrombopoiesis could be conﬁrmed during the
thrombocytopenia associated with acute hantavirus infection.
We also sought to further characterize the procoagulant changes
observed in vitro and in vivo. As the prediction of disease severity
is still of utmost importance in the treatment of hantavirus
infection, we particularly compared the relationship of our
ﬁndings with the clinical disease severity.2. Methods
2.1. Patients
The study was carried out at Tampere University Hospital and
University of Tampere School of Medicine, Finland. All patients
came from Pirkanmaa region and were hospitalized because of
serologically conﬁrmed [11]acute PUUV infection during the
period fromOctober 2010 to November 2015. Written informed
consent was obtained from all patients, and the Ethics Committee
of Tampere University Hospital approved the study protocol.
The study group consisted of 33 prospectively collected
consecutive adult patients (22 males), median age 45 years (range
21–67 years). Twenty-nine of the patients also participated in a
previous study determining platelet indices and functions during
acute PUUV infection.[10] Concomitant diseases included arterial
hypertension (n=5), diabetes mellitus (n=3), hypercholesterol-
emia (n=2), coronary heart disease (n=2), sleep apnea (n=2),
and celiac disease (n=2). One patient had chronic obstructive
pulmonary disease and 1 patient had undergone splenectomy
because of hereditary spherocytosis. No patient was under
immunosuppression or anticoagulation. Two patients received
anti-platelet therapy (acetylsalicylic acid, 100mg daily).2.2. Clinical and basic laboratory data
The following variables were recorded: smoking (yes/no), the
number of days from the onset of fever up to the acute phase
sample collection, the lowest diastolic and systolic blood pressure
(mmHg), clinical diagnosis of shock (yes/no), signs of bleeds (yes/
no), thromboembolic complications (yes/no), infusion of platelets
(yes/no), need for transient hemodialysis treatment (yes/no),
maximum and minimum daily urinary output (mL), and gain in
weight (kg). The last variable reﬂects ﬂuid retention during the
hospital stay in the oliguric phase of the disease. Complete blood2count, C-reactive protein (CRP), creatinine, and alanine
aminotransferase (ALT) were measured in plasma samples
according to clinical need. The laboratory analyses were carried
out at the Laboratory Centre of Pirkanmaa Hospital District
using standard methods.2.3. Assessment of serum TPO level and procoagulant
activity of plasma MPs
Serum samples to measure TPO level in the acute phase of the
disease were collected median 8 days (range 2–13 days) from the
beginning of fever. Citrated plasma for the measurement of
procoagulant activity of MPs and coagulation variables (plasma
ﬁbrinogen, prothrombin fragments F1+2, and D-dimer) as well as
whole blood for platelet indices (MPV and IPF%) and functions
(PFA-100 and Multiplate) were all collected at the same time,
median 7 days (range 1–12 days) from the beginning of fever. The
control samples were obtained at the recovery visit, median
43 days (range 31–60 days) from the beginning of fever.
For TPO, blood samples were collected and centrifuged at
1700g for 15minutes, and the serum was frozen at 700C.
Human Thrombopoietin Immunoassay Quantikine ELISA was
applied according the manufacturer’s instructions (R&D Sys-
tems,Minneapolis,MN). In healthy volunteers (n=38), the mean
level of serum TPO is 74.2pg/mL (ranging from nondetectable to
228pg/mL), according to the manufacturer. To measure
procoagulant activity of MPs in plasma, citrate-anticoagulated
(109nmol/L sodium citrate) blood samples were centrifuged
at 2000g for 15minutes. Plasma was then separated, further
centrifuged at 13,000g for 2minutes, and frozen at700C. Blood
sampling and processing of plasma were in accordance with the
instructions of ZYMYPHEN MP-Activity ELISA (ANIARA,
HYPHEN BioMed, West Chester, OH) that was applied for
analyses. TheMP- Activity test kit is a functional assaymeasuring
procoagulant activity of MPs derived from various cellular
sources.[12] In the assay, circulating MPs in the plasma sample
bind to Annexin V on the microplate surface and expose their
phospholipid surface, which allows prothrombin activation by
factor Xa and Va complex in the presence of calcium. The
exposed phospholipid concentration reﬂects the amount of
thrombin generation, which is measured using speciﬁc thrombin
substrate. According the manufacturer, concentration of MPs in
normal plasma is usually 5nmol/L (expressed as phophatidyl-
serine equivalent).2.4. Platelet indices and functions, and coagulation
variables
Measurement of MPV and IPF% as well as the assessment of
platelet functions with PFA-100 and Multiplate is described in
detail in our recent article.[10]
Fibrinogen was measured with a modiﬁcation of the Clauss
method (Multiﬁbren U, Siemens Healthcare Diagnostics), D-dimer
with an immunoturbidimetric assay (Tina-quant D-Dimer, Roche
Diagnostics, Mannheim, Germany), and F1+2 with an enzyme
immunoassay (Enzygnost F1+2, monoclonal, Siemens Healthcare
Diagnostics). The reference values were 1.7 to 4.0g/L for ﬁbrinogen,
0.5mg/L for D-dimer, and 69 to 229pmol/L for F1+2.2.5. Statistics
Since all continuous variables were skewed, medians and ranges
were calculated to describe the data. Numbers and percentages
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groups were based on Mann–Whitney U test or Kruskal–Wallis
test. To evaluate changes between the acute and the recovery
phase, Wilcoxon test was used. Relationships between the
continuous variables were examined using Spearman rank
correlation coefﬁcient. The limit of signiﬁcance was set at 0.05
(2-tailed). IBM SPSS Statistics for Windows, Version 22.0 (IBM
Corp., Armonk, NY) was used for computation.
3. Results
3.1. Clinical and basic laboratory ﬁndings
All 33 patients suffered from clinically typical and serologically
conﬁrmed[11] PUUV infection and were examined and hospital-
ized in the acute phase of the illness. All patients recovered.
Table 1 presents the clinical and basic laboratory ﬁndings of the
study patients. Eighteen (55%) of the patients were smokers.
Ten (30%) of the patients had signs of bleeding tendency,
mostly mild mucosal bleeds. No thromboembolic complications
were observed by the time of control (recovery phase) visit.
Three patients received platelet transfusions. Four (12%) of the
patientswere in clinical shock at the time of admission (ie, systolic
blood pressure <90mmHg together with clinical symptoms or
signs of shock). Two patients needed transient hemodialysis,
one of them and another patient were treated in the intensive
care unit.
At the time of the acute phase TPO andMP samples, 14 (45%)
patients had their platelet count 100109cells/L (median
118109cells/L, range 17–321109cells/L). At the same time-
point, the median creatinine value of the patients was 167mmol/L
(range 68–983mmol/L). In the control (recovery phase) sample,
the platelet count of all patients had recovered and in all patients
exceeded the lower limit of reference range 150109cells/L
(median 248109/L, range 197–507109cells/L).
3.2. Serum TPO level and its associations with clinical and
laboratory variables
Serum TPO level was nearly 4-fold higher acutely compared with
the control (Table 2). The ﬁnding of elevated serum TPO level
in the acute phase of the disease remained when patients wereTable 1
Clinical and basic laboratory ﬁndings in 33 patients with acute Puum
Clinical or Laboratory Variable Reference Values
Days from onset of illness
∗
Length of hospital stay, days
Systolic BP min, mmHg
Diastolic BP min, mmHg
Daily urinary output min, mL
Daily urinary output max, mL
Weight gain, kg†
Hematocrit min 0.35–0.46/0.50 f/m
Platelet count min, 109 cells/L 150-360
Leukocyte count max, 109 cells/L 3.4–8.2
CRP max, mg/mL <10
Creatinine max, mmol/L <95/<105 f/m
ALT max, U/L 10–45/70 f/m
ALT= alanine aminotransferase, BP=blood pressure, f= females, m=males, max=maximum, min=m
∗
The number of days of fever before the ﬁrst study sample.
† Gain in weight during hospital stay reﬂects the amount of ﬂuid accumulating in the body during the o
3divided into 2 groups (below or above themedian value) based on
the platelet count at the time of TPOmeasurement and the lowest
platelet count (Fig. 1). Large MPV and IPF% coincided with
elevated serum TPO level (Table 2), and an association was noted
between serum TPO level and IPF% (r= .44, P= .03).
High serum TPO level coinciding still with thrombocytopenia
associated with impaired platelet functions studied in whole
blood by both PFA-100 (Fig. 2) andMultiplate in the acute phase
of the disease. However, closure times studied with PFA-100
were only slightly prolonged acutely compared with the control
despite the lowered platelet count (Table 2). Platelet functions
studiedwithMultiplate are described in detail elsewhere.[10] High
serum TPO associated with impaired aggregation triggered with
all 5 agonists (for adrenalin, r=0.69, P<0.001; for adenosine
diphosphate, r=0.77, P<0.001; for arachidonic acid, r=
0.67, P=0.001; for collagen, r=0.63, P= .002; for thrombin
receptor-activating peptide, r=0.50, P= .03; for ristocetin,
r=0.73, P<0.001).
SerumTPO level associatedwith the length of hospital stay (r=
0.40, P=0.04). A negative association prevailed between TPO
and minimum hematocrit (r=0.45, P=0.02), platelet count at
the time of TPO measurement (r=0.71, P<0.001), and
minimum platelet count (r=0.67, P<0.001). Signs of bleeding
tendency did not, however, associate with serum TPO level. No
association was found between serum acute-phase TPO level and
plasma creatinine, minimum or maximum daily urinary output,
gain of weight, or need of transient hemodialysis. Minimum
systolic or diastolic blood pressure and smoking did not associate
with serum TPO level either (data not shown).3.3. Plasma coagulation variables
D-dimer was 7-fold higher acutely compared with the value
measured at control visit in this group of PUUV-infected patients.
F1+2 was clearly elevated (Table 2) and it associated with serum
TPO level (r=0.47, P=0.03). Both D-dimer and F1+2 associated
with minimum platelet count (r=0.48, P=0.01 and r=0.46,
P=0.02, respectively), plasma creatinine level at the time of
the measurement (r=0.57, P=0.002 and r=0.50, P=0.008,
respectively) and maximum plasma creatinine (r=0.54,
P=0.004 and r=0.42, P=0.03, respectively).ala hantavirus infection.
Median Range
7 1–12
7 3–22
108 60–135
67 36–83
800 20–2320
4880 2000–9610
3.8 0.5–11.3
0.35 0.25–0.41
42 4–150
12.1 4.0–45.0
74 21–244
296 71–983
59 9–2076
inimum.
liguric phase.
Table 2
Serum thrombopoietin level, platelet indices, platelet functions studied by PFA-100 and coagulation variables during Puumala hantavirus
infection at acute and at the recovery phase.
Variable (unit) Acute Value Median (Range) Recovery Value Median (Range) P Reference Values
TPO, pg/mL 207 (56–1258) 58 (11–241) <0.001 ND-228
MPV, fL 11.0 (9.4–13.1) 10.5 (9.2–12.0) 0.006 9.0–12.0
IPF% 7.4 (1.8–23.8) 2.3 (0.8–5.2) <0.001 1.0–5.0
COLL/ADR, s 130 (70–301) 109 (87–250) 0.840 82–150
COLL/ADP, s 92 (56–301) 89 (63–131) 0.055 62–100
Fibrinogen, g/L 4.2 (2.2–9.6) 3.4 (2.6–4.9) 0.005 1.7–4.0
F1+2, pmol/L 704 (284–1875) 249 (118–556) <0.001 69–229
D-dimer, mg/L 2.8 (0.6–34) 0.4 (0.2–1.1) <0.001 0.5
COLL/ADR= collagen/adrenalin agonist, F1+2=plasma prothrombin fragments, IPF%= immature platelet fraction %, MPV=mean platelet volume, ND=non-detectable, s= second, TPO= serum
thrombopoietin level.
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There was no difference in the activity of MPs derived from
various cellular origins in the acute phase of PUUV infection
compared with the recovery phase. No associations betweenMPs
and clinical or laboratory variables determined in this study could
be observed. However, in patients with plasma creatinine value
below themedian of 167mmol/L,MPs’ procoagulant activity was
increased acutely compared with the control (median 2.7nmol/L,
range 0.9–5.3nmol/L vs. median 1.8nmol/L, range 0.8–3.2nmol/
L, P=0.04). Likewise,MPs’ activity was increased acutely among
patients with maximum plasma creatinine value below the
median of 296mmol/L (median 2.6nmol/L, range 1.0–5.3nmol/L
vs. median 1.8nmol/L, range 0.8–3.2nmol/L, P=0.03). MPs’
activity in the acute phase of the disease did not differ from the
activity observed at the recovery when patients were divided into
2 groups (below or above median value) based on the platelet
count at the time of the MPs’ activity measurement or the lowest
platelet count.
3.5. Severely ill patients
Two patients were severely ill and laboratory ﬁndings of them are
described in Table 3. Patient 1 was a 61-year-old previously
smoking male who needed intensive care treatment, and patient 2
was a 28-year-old smoking male with a need of temporary
hemodialysis treatment. Both patients had a very low platelet
count minimum, high acute TPO and IPF%, and prolonged
closure times measured with PFA-100.Figure 1. Serum thrombopoietin level in 33 patients during acute Puumala
hantavirus infection. (A) Patients with platelet count at the time of the
measurement  or > the median of 118109cells/L. Serum thrombopoietin
median 247pg/mL, range 70–1258pg/mL vs. median 118pg/mL, range
56–336pg/mL, P= .004. (B) Patients with the lowest platelet count  or > the
median of 42109cells/L. Serum thrombopoietin median 258pg/mL, range
74–1258pg/mL vs. median 133pg/mL, range 56–336pg/mL, P=0.02.4. Discussion
The most evident ﬁnding of our study was the 4-fold elevated
level of serum TPO during acute PUUV infection compared with
the recovery phase. Elevated platelet indices MPV and IPF%
imply that bone marrow response to the TPO stimulus is
adequate, and decreased platelet count observed during the acute
phase of the disease is contributed by factors other than impaired
platelet production. The association of high TPO with decreased
platelet functions measured both with PFA-100 and Multiplate
was observed during thrombocytopenia. It suggests that active
thrombopoiesis, though able to provide with clinical hemostasis,
is not sufﬁcient to overcome the diminished functional capacity
noted in vitro. TPO did not associate with AKI, the major
outcome of HFRS. The markedly increased F1+2 and D-dimer
further support the idea of platelet consumption in the
vasculature by ongoing coagulation and ﬁbrinolysis. Their
association with variables reﬂecting AKI is a novel ﬁnding in4Finnish PUUV-patients, but in line with a previous observation of
high D-dimer under severe disease condition in Swedish
patients.[3] We could not detect any increase in MPs’ procoa-
gulant activity during acute PUUV infection. That ﬁnding,
however, needs to be explored in more detail, but MPs have been
[13]
[14]
Figure 2. Association of serum thrombopoietin level with platelet functions
studied with collagen/adrenalin and collagen/adenosine diphosphate agonists
of PFA-100. (A) r=0.69, P<0.001. (B) r=0.77, P<0.001.
Table 3
Laboratory ﬁndings of the two patients with severe Puumala
hantavirus infection in the acute phase and at the recovery.
Laboratory Finding Patient 1 Patient 2
TPO acute/recovery, pg/mL 638/61 648/48
MP acute/recovery, pg/mL 0.9/2.0 5.4/1.0
Plasma creatinine acute, mmol/L 574 429
Plasma creatinine max, mmol/L 641 756
Platelet count acute, 109 cells/L 85 24
Platelet count min 109 cells/L 4 17
IPF% acute 11.4 13.6
PFA COLL/ADR
acute/recovery, s 239/103 300/99
PFA COLL/ADP
acute/recovery, s 146/86 206/101
IPF%= immature platelet fraction %, max=maximum, min=minimum, MP=microparticles’
procoagulant activity, TPO= serum thrombopoietin level, PFA COLL/ADR/ADP=platelet function
analyzer 100 collagen/adrenalin/adenosine diphosphate agonist.
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the hantavirus infection.
TPO is a humoral growth factor characterized for its ability to
stimulate the production and differentiation of megakaryocytes.
TPO is mainly produced in the liver and kidneys, and binding
of TPO with its receptor c-mPl on platelet surface initiates
intracellular signaling including activation of JAK2/signal trans-
ducers and activators of transcription (STAT) pathway. Plasma
TPO concentrations vary usually inversely with the platelet
count, but mechanisms other than platelet count that affect TPO
have also been identiﬁed.[14]
High plasma concentration of TPO and low platelet count have
been reported in patients with Puumala hantavirus, dengue virus,
and human immunodeﬁciency virus (HIV) infection.[9,15,16] In
HIV-infected patients, c-mPl expression per platelet is elevated,
and recombinant human megakaryocytic growth factor reduces
the c-mPl expression and restores platelet count to normal
level.[16] In a macaque model of HIV, transforming growth factor
b (TGFb) downregulates TPO, and combined antiretroviral
therapy corrects both plasma TGFb level and platelet count.[17]
In severe acute respiratory syndrome induced by a novel
coronavirus, TGFb inhibits the effect of high TPO on mega-
karyocytopoiesis.[18] Inﬂammatory mediator interleukin 6 (IL-6),5however, increases TPO production both in vitro and in vivo.
Our ﬁnding of high TPO during acute PUUV infection is in line
with a previous observation [9] and consistent with both low
platelet count and high plasma IL-6 in acute PUUV infection .[19]
High plasma level of TPO is suggested to predict sepsis severity in
the early disease phase.[20] We now noted an association between
plasma level of TPO and the length of hospital stay, the latter
variable describing overall disease severity. However, in this
study, TPO had no association with any of the variables reﬂecting
AKI that is the major clinical determinant of hantavirus-induced
HFRS.
The inverse association between serum TPO level and platelet
functions measured by both PFA-100 and Multiplate was clear,
as was the positive association between TPO and IPF%. TPO has
been reported to enhance platelet activation during burn injury
[21] and increase platelet adhesion under ﬂow.[22] Moreover, high
TPO has a priming effect on platelet aggregation in response to
different agonists.[23] In this study, the effect of low platelet count
on platelet aggregation was not compensated by the simulta-
neously occurring elevated TPO level and high proportion of
young platelets. As major bleeding problems were avoided and
no thromboembolic complications were noted, hemostasis
appears clinically balanced in spite of laboratory ﬁndings
reﬂecting impairment of primary hemostasis.
MPs and exosomes are small membrane vesicles that are
released from different cell types by exocytic budding in response
to cellular activation or apoptosis. They are now seen as
mediators of cell-to-cell communication.[24] They express
phospholipids and are classically thought to function as
procoagulants supporting thrombin formation and facilitating
coagulation by factor VII/TF-dependent and -independent path-
ways. Elevated concentrations of MPs deriving from platelets,
endothelial cells, and monocytes have been reported in arterial
and venous thrombotic diseases as well as in autoimmune
conditions, infectious diseases, hematologic disorders, and
cancer. However, the clinical signiﬁcance of these ﬁndings
remains controversial.[25,26] Flow cytometry is the most widely
used method to study MPs.[27]
Increased TF expression ,[5] enhanced thrombin formation,[6]
and signs of cellular activation and apoptosis[1] are all present
during acute hantavirus infection, and we presumed to detect
higher level of MPs’ procoagulant activity during the acute phase
of the disease compared with the recovery phase. That was,
[7] Strandin T, Hepojoki J, Laine O, et al. Interferons induce STAT1-
Laine et al. Medicine (2016) 95:52 Medicinehowever, the ﬁnding only among patients with mild kidney
injury. In this study, increased thrombin formation (F1+2) and
ﬁbrinolysis (D-dimer) associated with the severity of AKI, and the
attachment of platelet-derived MPs to ﬁbrin clots especially in
patients with more severe kidney injury could plausibly explain
our observation.[13,28] Preanalytical measures as well as analyti-
cal methods in the detection of MPs’ activity are crucial[29] and
even if the instructions of the ELISA-assay manufacturer were
vigorously followed, the issues regarding methodology cannot be
completely excluded.[12] The sample size of the study was, though
not large but probably sufﬁcient, as the difference of serum TPO
level in the acute phase of the disease compared with the recovery
could be veriﬁed. MPs’ procoagulant activity did not associate
with any of the variables depicting disease severity, and it failed to
predict clinical outcome in this group of patients with acute
Puumala hantavirus infection.
Plasma level of TPO or MPs’ activity could not predict severe
hantavirus disease in the 33 patients of this study, but the
2 severely ill patients had particularly high TPO level and
percentage of young platelets as well as very clearly impaired
platelet functions according to PFA-100 in the acute phase of the
disease (Table 3). The ﬁnding regarding MPs’ activity on these 2
individual patients was inconsistent and may stem from patients
medical history, current treatment as well as the condition
itself.
In conclusion, serum TPO is upregulated and the production of
platelets is enhanced during acute Puumala hantavirus disease.
Serum TPO does not predict disease severity in terms of AKI.
Biomarkers of thrombin generation and especially ﬁbrinolysis are
high in the absence of clinical thrombosis or major bleedings, and
they associate with adverse kidney outcome. As thrombopoiesis
is active and the proportion of young platelets is high, measuring
the activity of platelet-derived MPs with ﬂow cytometry might
clarify the role of MPs in the pathogenesis of HFRS.Acknowledgements
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